In this issue:
Neoadjuvant endocrine therapy in postmenopausal HR+/HER2– disease
Physical activity and risk of five key diseases
Regular physical activity reduces risk of recurrent disease
70-gene signature aids treatment decisions in early disease
The Recurrence Score changes treatment recommendations
Patient-reported outcomes and cosmesis after hypofractionated WBT
Continuous low-dose oral chemotherapy in HR– early disease
Younger age prognostic for breast cancer outcomes?
First-line bevacizumab/capecitabine in HER2– disease
Safety data for everolimus+exemestane in advanced disease
T-DM1+docetaxel ± pertuzumab in advanced HER2+ diseae
Please login below to download this issue (PDF)